
Illumina (ILMN) Stock Forecast & Price Target
Illumina (ILMN) Analyst Ratings
Bulls say
Illumina is a dominant player in the genomics market, with a focus on providing tools and services for genetic analysis in both clinical and academic settings. Despite some recent challenges with instrument mix and competition, the company remains poised for sustained growth in the clinical market and has a strong pipeline of products in development. The recent acceleration in clinical growth shows potential for long-term success and the company's strategic investments in areas like BioInsight and the SomaLogic acquisition demonstrate its commitment to continued expansion. While there are risks to consider, including ongoing uncertainties in China and potential competition, the overall outlook for Illumina is positive and the company is well-positioned for continued growth in the long term.
Bears say
Illumina is a leading provider of genetic analysis tools and services, but the company's reliance on high-throughput sequencing instruments and consumables puts it at risk of facing competitive pressure and potential pricing pressures. Customers typically place multi-quarter orders in advance, providing good short-term visibility, but there are concerns about shelf life and stocking dynamics. Additionally, while the company has experienced strong growth in clinical markets, sustained growth at this rate may be difficult to maintain and academic weakness is an industry-wide problem. Overall, the company's valuation is reasonable but its earnings are burdened by past overbuild, and any further weakness in demand could impact performance.
This aggregate rating is based on analysts' research of Illumina and is not a guaranteed prediction by Public.com or investment advice.
Illumina (ILMN) Analyst Forecast & Price Prediction
Start investing in Illumina (ILMN)
Order type
Buy in
Order amount
Est. shares
0 shares